newsfilter
← Earnings
Earnings Releases·

Atea Pharmaceuticals — Third Quarter 2026 Earnings Summary

  • Reported net loss of $32.2 million ($0.40/share) for Q3 2026, a 23% improvement year-over-year from $42.0 million ($0.53/share), driven by reduced R&D and G&A expenses; cash and marketable securities declined to $191.2 million from $301.8 million at year-end 2025.
  • Secured a $200 million credit facility with Hercules Capital, drawing $65 million at closing in November 2026, extending the cash runway to mid-2028 with potential for further extension via additional borrowings.
  • Phase 3 C-BEYOND trial met primary and secondary endpoints with 93.91% SVR rate versus 94.75% for Epclusa; Phase 3 C-FORWARD is fully enrolled with results anticipated in early 2027 to support a mid-2027 NDA submission for BEM/RZR.
  • Progress on HEV candidate AT-587 includes completion of single ascending dose Phase 1, with multiple ascending dose study ongoing and proof-of-concept study planned for H1 2027.
Company
ATEA PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology